Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Indian J Ophthalmol ; 2012 Nov-Dec; 60(6): 527-530
Article in English | IMSEAR | ID: sea-144913

ABSTRACT

Background: Retinopathy of prematurity (ROP) is the main cause of visual impairment in preterm newborn infants. Objective: This study was conducted to determine whether insulin-like growth factor binding protein -3 (IGFBP-3) is associated with proliferative ROP and has a role in pathogenesis of the disease in premature infants. Materials and Methods: A total of 71 preterm infants born at or before 32 weeks of gestation participated in this study. Studied patients consisted of 41 neonates without vaso-proliferative findings of ROP as the control group and 30 preterm infants with evidence of severe ROP in follow up eye examination as the case group. Blood samples obtained from these infants 6-8 weeks after birth and blood levels of IGFBP-3 were measured using enzyme-linked immunosorbent assay (ELISA). Results: The mean gestation age and birth weight of the studied patients were 28.2±1.6 weeks and 1120.7±197 gram in the case group and 28.4±1.6 weeks and 1189.4±454 gram in the control group (P=0.25 and P=0.44 respectively). The infants in the case group had significantly lower Apgar score at first and 5 min after birth. Insulin-like growth factor binding protein -3 (IGFBP-3) was significantly lower in the patients with proliferative ROP than the patients without ROP [592.5±472.9 vs. 995.5±422.2 ng/ml (P=0.009)]. Using a cut-off point 770.45 ng/ml for the plasma IGFBP-3, we obtained a sensitivity of 65.9% and a specificity of 66.7% in the preterm infants with vasoproliferative ROP. Conclusion: Our data demonstrated that the blood levels IGFBP-3 was significantly lower in the patients with ROP and it is suspected that IGFBP-3 deficiency in the premature infants may have a pathogenetic role in proliferative ROP.


Subject(s)
Humans , Infant, Premature , Infant, Newborn , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/blood , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/blood , Retinopathy of Prematurity/blood , Retinopathy of Prematurity/epidemiology , Retinopathy of Prematurity/etiology
2.
Chinese Journal of Oncology ; (12): 328-333, 2010.
Article in Chinese | WPRIM | ID: wpr-260405

ABSTRACT

<p><b>OBJECTIVE</b>To explore the relationship between the methylation status of CpG islands in the promoter region of 10 genes in breast cancer cells and their sensitivity to 5-fluouracil (5-Fu), and to identify the genes responsible for the 5-Fu resistance in breast cancer.</p><p><b>METHODS</b>Three cell lines (differently resistant to chemotherapy) were used in this study: Bcap-37 (IC(50): 289.77 microg/ml), T47D (IC(50): 134.16 microg/ml) and ZR-75-30 (IC(50): 4.20 microg/ml). The methylation profile of 10 genes (BAG1, C11ORF31, CBR1, CBR4, GJA1, FOXL2, IGFBP6, P4HA1, SRI and TYMS) in the 3 breast cancer cell lines was determined by methylation specific PCR. The steady-state mRNAs of ABCC8, CHFR and IGFBP6 genes were quantified by real-time RT PCR analysis.</p><p><b>RESULTS</b>Among the 10 genes, only genes IGFBP6 and FOXL2 displayed differential DNA methylation pattern between the 5-Fu-resistant and 5-Fu-sensitive cell lines. The mRNA expression level of genes PRSS21, LOX, IGFBP6, ABCC8 and CHFR was quantified by real-time RT-PCR analysis. Except for CHFR, the expression level of the other 4 genes was correlated with the methylation status of CpG islands, namely, a lower expression level with methylation status and a higher level with demethylation status.</p><p><b>CONCLUSION</b>The results of the present study have demonstrated that there are 8 genes with differential methylation status in chemosensitive and chemoresistant breast cancer cell lines, i.e. two genes more than the six genes we reported previously. Our findings provide both mechanistic insights for the drug resistance of breast cancer and the basis for further studies on potential application of the DNA methylation in this set of genes for prediction of chemosensitivity of breast cancer.</p>


Subject(s)
Humans , Antimetabolites, Antineoplastic , Pharmacology , Breast Neoplasms , Genetics , Metabolism , Pathology , Cell Line, Tumor , CpG Islands , Genetics , DNA Methylation , Drug Resistance, Neoplasm , Fluorouracil , Pharmacology , Forkhead Box Protein L2 , Forkhead Transcription Factors , Genetics , Metabolism , Gene Expression Regulation, Neoplastic , Insulin-Like Growth Factor Binding Protein 6 , Genetics , Metabolism , Promoter Regions, Genetic , RNA, Messenger , Metabolism
3.
Experimental & Molecular Medicine ; : 478-486, 2009.
Article in English | WPRIM | ID: wpr-107288

ABSTRACT

Osteoblasts can synthesize the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs), which may either enhance or attenuate IGF-stimulated bone cell proliferation. Since estrogen induced osteoblastic differentiation and proliferation through an estrogen-responsive gene in target cells, we investigated the effects of estrogen on IGFBP-6 expression in the human osteoblastic-like cell line SaOS-2. Expressions of IGFBP-6 protein and mRNA increased 2.8 and 2-fold, respectively, in the presence of 17-beta-estradiol (E2) (0.01 to 1 micrometer) and estrogen receptor (ER) in SaOS-2 cells. On the other hand, E2 induced a 2-fold increase in SaOS-2 cell proliferation. To identify genomic sequences associated with estrogen responsiveness, the 5'-promoter region (-44 to +118) of the IGFBP-6 gene was cloned into a chloramphenicol acetyltransferase (CAT) reporter vector. E2 induced a 3-fold increase in CAT activity in SaOS-2 cells transiently transfected with this construct. Identification of the estrogen-responsive element (ERE) [5'-CCTTCA CCTG-3'] (-9 to +1) in this IGFBP-6 gene promoter region was confirmed using electromobility shift assays and deletion analysis. This functional ERE was important for E2-induced trans-activation of the IGFBP-6 gene. These results demonstrate that E2 exhibits a positive effect on IGFBP-6 gene transcription through estrogen-liganded ER binding to the functional ERE in the IGFBP-6 gene promoter in SaOS-2 cells.


Subject(s)
Humans , Blotting, Western , Cell Proliferation , Chloramphenicol O-Acetyltransferase/metabolism , Electrophoretic Mobility Shift Assay , Estradiol/pharmacology , Estrogen Receptor alpha/genetics , Estrogens/pharmacology , Insulin-Like Growth Factor Binding Protein 6/genetics , Osteoblasts/drug effects , Promoter Regions, Genetic/genetics , RNA, Messenger/genetics , Response Elements , Reverse Transcriptase Polymerase Chain Reaction , Transcriptional Activation , Tumor Cells, Cultured
4.
Acta Academiae Medicinae Sinicae ; (6): 735-739, 2009.
Article in Chinese | WPRIM | ID: wpr-301617

ABSTRACT

<p><b>OBJECTIVE</b>To study the nuclear localization of insulin-like growth factor binding protein-6(IGFBP-6) in PC-3M cells.</p><p><b>METHODS</b>The two fragments of the nuclear localization sequence (NLS)-deleted IGFBP-6 and the NLS-mutated IGFBP-6 were obtained by overlapping PCR, and then the fragment was inserted into a pEGFP-C1 vector. PC-3M cells were transfected with the expression constructs containing wild-type IGFBP-6 or the two mutants (pEGFP-C1-BP6 Delta NLS and pEGFP-C1-BP6-Mut), and the different distribution of the three EGFP-fusion proteins was observed by confocal laser microscope. The statistical analysis of the ratio of the nuclear fluorescence to the cytoplasmic fluorescence (Fn/c) was performed. Results Confocal microscopic images of transfected cells showed that the green fluorescence of EGFP-IGFBP-6 was concentrated mostly in the nuclei, whereas the control cells expressing EGFP showed green fluorescence distributed uniformly. The results of Fn/c from EGFP and EGFP-IGFBP-6 were significant different (P<0.05). The NLS-deleted IGFBP-6 completely eliminated nuclear accumulation of the green fluorescent signal; in contrast, nuclear accumulation was only slightly reduced for the NLS-mutated IGFBP-6; compared with wild-type IGFBP-6, both mutants were significantly different (P<0.05). Conclusions IGFBP-6 can be translocated to the nucleus in PC-3M cell that is mediated by a putative NLS sequence. Our study provides new evidence for further studies on the insulin-like growth factor-independent activity of IGFBP-6.</p>


Subject(s)
Humans , Cell Line, Tumor , Cell Nucleus , Metabolism , Genetic Vectors , Insulin-Like Growth Factor Binding Protein 6 , Genetics , Metabolism , Plasmids , Genetics , Protein Transport , Genetics , Transfection
5.
Chinese Journal of Industrial Hygiene and Occupational Diseases ; (12): 223-226, 2008.
Article in Chinese | WPRIM | ID: wpr-304030

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the effect of the environmental carcinogenic factor-TCDD (2, 3, 7, 8-tetrachlorodibenzo-p-dioxin) on cell apoptosis and gene regulation of insulin-like growth factor binding protein 6 (IGFBP-6) in osteogenic sarcoma (SaOS-2) cells.</p><p><b>METHODS</b>The SaOS-2 cells were cultured with TCDD (1 x 10(-9), 1 x 10(-8), 1 x 10(-7) mol/L) for 24 hours. The MTT reduction assay and flow cytometry were used to measure the cell proliferation and the cell apoptosis in TCDD-treated SaOS-2 cells. The Nitrophenol phosphate salt method was used to measure activity of alkaline phosphatase (ALP) in SaOS-2 cells. The IGFBP-6 mRNA and protein in SaOS-2 cells were detected by reverse transcription polymerase chain reaction (RT-PCR) and western blotting analysis.</p><p><b>RESULTS</b>SaOS-2 cell proliferation was up-regulated with TCDD (1 x 10(-9), 1 x 10(-8), and 1 x 10(-7) mol/L) about 20%, 47% and 93% (18.4 +/- 4.5, 22.5 +/- 3.6 and 29.4 +/- 4.2), respectively. The synthesis of ALP was up-regulated about 28%, 95%, and 142% (1.12 +/- 0.28, 1.58 +/- 0.14 and 1.96 +/- 0.17), respectively (P < 0.05). The cell apoptosis was down-regulated in dose-dependent biological manner about 5%, 26% and 52%, respectively (P < 0.05). The expression of IGFBP-6 mRNA and protein was decreased in 1 x 10(-7) mol/L TCDD-treated SaOS-2 cells about 76% and 72% (P < 0.05).</p><p><b>CONCLUSION</b>TCDD at low concentration may have the negative effect on cell apoptosis and down-regulation on gene expression of IGFBP-6 in SaOS-2 cells.</p>


Subject(s)
Humans , Apoptosis , Cell Line, Tumor , Cell Proliferation , Insulin-Like Growth Factor Binding Protein 6 , Genetics , Metabolism , Osteosarcoma , Metabolism , Pathology , Polychlorinated Dibenzodioxins , Toxicity , RNA, Messenger , Genetics
6.
Korean Journal of Pediatrics ; : 884-891, 2004.
Article in Korean | WPRIM | ID: wpr-148791

ABSTRACT

PURPOSE: PTEN/MMAC1, a novel tumor suppressor gene, is mutated in a variety of advanced and metastatic cancers. It acts as a phosphatase, and thereby, regulates the PI-3 kinase/Akt pathway. In this study, we examined to evaluate the new function of anti-tumor effects of PTEN/MMAC1 through the regulation of the IGFs-IGFBPs in gastric cancer cells. METHODS: PTEN/MMAC1 was expressed in an adenovirus-mediated gene delivery system and introduced into gastric cancer cells(SNU-484 & SNU-668) in vitro. The effect of cell growth and the expression of IGFs and IGFBPs after Ad/PTEN infection was analyzed by MTT assay, RT-PCR and Western immunoblot. RESULTS: Ad/PTEN infected cells were inhibited in cell growth compared with moak cells and Ad/ LacZ infected cells. Overexpression of PTEN/MMAC1 induced decrease in expression of IGF-I, -II and IGF-I receptors which are known as growth prompt molecules in a variety of cancers. Of the six IGFBPs, the expressions of IGFBP-4 and IGFBP-6 were decreased in Ad/PTEN infected cells. In contrast, IGFBP-3 expression was markedly increased by up to 3-fold in Ad/PTEN infected cells. Overexpression of PTEN/MMAC1 inhibited the activation of Akt/PKB pathway, but had no effect on the MAPK pathway. CONCLUSION: These findings suggest that the tumor suppressor function of PTEN/MMAC1 is, at least in part, mediated through the down-regulation of IGF-I abd IGF-II, and up-regulation of IGFBP-3 in gastric cancer cells by the inhibition of PI-3 kinase pathway.


Subject(s)
Blotting, Western , Down-Regulation , Gene Transfer Techniques , Genes, Tumor Suppressor , Insulin-Like Growth Factor Binding Protein 3 , Insulin-Like Growth Factor Binding Protein 4 , Insulin-Like Growth Factor Binding Protein 6 , Insulin-Like Growth Factor Binding Proteins , Insulin-Like Growth Factor I , Insulin-Like Growth Factor II , Phosphatidylinositol 3-Kinase , Phosphatidylinositol 3-Kinases , Receptor, IGF Type 1 , Stomach Neoplasms , Up-Regulation
7.
Chinese Journal of Medical Genetics ; (6): 490-494, 2003.
Article in Chinese | WPRIM | ID: wpr-329427

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the antiestrogenic effect of environment teratogen on the gene expression of insulin-like growth factors (IGFs) family in osteoblast cells during rat skeleton development.</p><p><b>METHODS</b>The fetal rat models with congenital skeleton malformation were constructed by treating 20 female Wistar rats with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on pregnant day 10. The MC-3T3-E1 cells were cultured with estrogen, TCDD, or a combination of the two chemicals for 24 hours. The IGF-II and IGFBP-6 mRNA levels in rat calvaria bone tissue and MC-3T3-E1 cells were detected by reverse transcription-polymerase chain reaction. Flow cytometer was used to determine the cell proliferation.</p><p><b>RESULTS</b>TCDD at the concentration of 5-15 microg/kg induced developmental skeleton defect of fetal rat, and the effect was dose-dependent. The expression of IGF-II mRNA gene was enhanced by estrogen in rat calvaria bone tissue and MC-3T3-E1 cells, whereas IGFBP-6 mRNA was decreased. Estrogen increased the cell proliferation in MC-3T3-E1 cells. TCDD, however, inhibited the effect of estrogen on regulation of IGF-II gene and IGFBP-6 gene as well as MC-3T3-E1 cell proliferation.</p><p><b>CONCLUSION</b>These findings provide the evidence that TCDD can induce congenital fetal skeleton malformation under the condition of high estrogen level in pregnant Wistar rats. TCDD has antiestrogenic effect and hence exerts negative influence on the osteoblast cells through target IGF-II and IGFBP-6 of IGFs family.</p>


Subject(s)
Animals , Female , Rats , Abnormalities, Drug-Induced , Bone and Bones , Congenital Abnormalities , Dose-Response Relationship, Drug , Estrogen Receptor Modulators , Toxicity , Insulin-Like Growth Factor Binding Protein 6 , Genetics , Insulin-Like Growth Factor II , Genetics , Osteoblasts , Metabolism , Polychlorinated Dibenzodioxins , Toxicity , RNA, Messenger , Rats, Wistar
8.
Acta bioquím. clín. latinoam ; 32(4): 471-516, dic. 1998. ilus, tab
Article in Spanish | LILACS | ID: lil-236524

ABSTRACT

El sistema de los factores de crecimiento insulino-símiles (IGF) se halla involucrado en diferentes aspectos de la regulación celular y tisular, como así también en el desarrollo y el crecimiento corporal. Este sistema depende de la interacción entre ligandos (IGF-I, IGF-II), receptores (Tipo I, Tipo II), proteínas ligadoras o transportadoras (IGFBP-1 a -6), y proteasas específicas para las IGFBPs. La acción de los IGFs se encuentra regulada por diferentes factores y estímulos, tales como la hormona de crecimiento, que actúan a diversos niveles. El desarrollo de nuevos métodos para analizar los diferentes componentes del sistema de los IGFs ha aportado elementos adicionales para la evaluación, diagnóstico y seguimiento de pacientes con alteraciones del crecimiento


Subject(s)
Humans , Animals , Rats , Failure to Thrive/diagnosis , Insulin-Like Growth Factor Binding Proteins/physiology , Receptors, Somatomedin/genetics , Somatomedins/genetics , Failure to Thrive/etiology , Insulin-Like Growth Factor Binding Protein 1 , Insulin-Like Growth Factor Binding Protein 2 , Insulin-Like Growth Factor Binding Protein 3 , Insulin-Like Growth Factor Binding Protein 4 , Insulin-Like Growth Factor Binding Protein 5 , Insulin-Like Growth Factor Binding Protein 6 , Somatomedins/physiology
9.
Journal of Korean Society of Endocrinology ; : 34-44, 1998.
Article in Korean | WPRIM | ID: wpr-147849

ABSTRACT

BACKGROUND: Sex steroid hormones are believed to play an important role in the genesis and growth of uterine myoma. Several studies suggest a possible role of insulin-like growth factor(IGF) as a mediator of estradiol in uterine myama. We have recently demonstrated that some IGF binding proteins(IGFRPs) messenger ribonucleic acid(mRNA) expressions in myoma are dependent on the in vivo esttogen status. The purposes of this study are to evaluate the in vitro effects of sex steroid hormones including estrogen on the IGFBPs gene expression in tissues from uterine myoma and adjacent normal myometrium. METHODS: Tissues from myoma and adjacent normal myometrium of patients with uterine myoma during early proliferative phase of menstrual cycle were cultured in the absence(control) and presence of 17b-estradiol(10M/L) or/and progesterone(10M/L) for 3 days. The IGFBPs mRNA expressions in these explants were analyzed by Nothern blot using specific human complementary deoxyribonucleic acid(cDNA) probes. RESULTS: The addition of 17b-estradiol, progesterone alone and in combination to conditioned media of explants from myoma and adjacent normal myornetrium did not result in any changes in the expression of IGFBP-2, IGFBP-4, IGFBP-5, and IGFBP-6 mRNA. With progesterone addtion, lGFBP-3 rnRNA expression was significantly reduced in myoma explant but not in adjacent ncemal myometrium explant. There was no significant change in the IGFBP-3 mRNA expression with 17b-estradiol and with the combination of both 17b-estradiol and progesterone. CONCLUSION: 17b-estradiol does not affect IGFBPs gene expression in the myoma and adjacent normal myometrium explant regardless of the presence of progesterone in vitro. However progesterone alone induces a decrease in IGFBP-3 synthesis in myoma explant.


Subject(s)
Animals , Female , Humans , Mice , Culture Media, Conditioned , Estradiol , Estrogens , Gene Expression , Gonadal Steroid Hormones , Insulin-Like Growth Factor Binding Protein 2 , Insulin-Like Growth Factor Binding Protein 3 , Insulin-Like Growth Factor Binding Protein 4 , Insulin-Like Growth Factor Binding Protein 5 , Insulin-Like Growth Factor Binding Protein 6 , Insulin-Like Growth Factor Binding Proteins , Leiomyoma , Menstrual Cycle , Myoma , Myometrium , Progesterone , RNA, Messenger
10.
Actual. pediátr ; 7(3): 96-100, sept. 1997. graf
Article in Spanish | LILACS | ID: lil-292612

ABSTRACT

El objetivo de este estudio, consistió en evaluar la utilidad de la cuantificación de IGF-I en suero, como método de evaluación temprana de recuperación nutricional en los pacientes con desnutrición (DNT). Fueron incluídos 20 niños con DNT crónica en un estudio experimental clínico aaleatorizado controlado en donde se realizaron mediciones antropométricas (peso, talla) y se obtuvieron las relaciones de peso/edad, peso/talla y talla/edad y se tomaron muestras de suero para cuantificación de IGF-I iniciales y a lasemana, 2 semanas, 3 semanas de iniciar la alimentación. Simultáneamente se evaluaron los cambios antropométricos durante el tiempo de estudio. Los niveles de IGF-I iniciales fueron de 203 mas o menos 36.5 ng/ml, a la semana 196.3 mas o menos 114.7, a las 2 semanas 179.5 mas o menos 87.1 y a las 3 semanas fue de 253.3 mas o menos 126.4 ng/ml (p= 0.02). No hubo cambios significativos en las medidas antropométricas durante el mismo período. En conclusión, los niveles séricos de IGF-I es un método útil para evaluar la efectividad del manejo nutricional


Subject(s)
Humans , Child , Child, Preschool , Insulin-Like Growth Factor Binding Protein 6 , Nutrition Rehabilitation/methods
SELECTION OF CITATIONS
SEARCH DETAIL